| Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 … NI Paton, J Musaazi, C Kityo, S Walimbwa, A Hoppe, A Balyegisawa, ... The Lancet HIV 9 (6), e381-e393, 2022 | 86 | 2022 |
| Dolutegravir as first-or second-line treatment for HIV-1 infection in children A Turkova, E White, HA Mujuru, AR Kekitiinwa, CM Kityo, A Violari, ... New England Journal of Medicine 385 (27), 2531-2543, 2021 | 74 | 2021 |
| Simplified dolutegravir dosing for children with HIV weighing 20 kg or more: pharmacokinetic and safety substudies of the multicentre, randomised ODYSSEY trial PDJ Bollen, CL Moore, HA Mujuru, S Makumbi, AR Kekitiinwa, E Kaudha, ... The Lancet HIV 7 (8), e533-e544, 2020 | 37 | 2020 |
| ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested … CL Moore, A Turkova, H Mujuru, A Kekitiinwa, A Lugemwa, CM Kityo, ... BMC infectious diseases 21, 1-14, 2021 | 31 | 2021 |
| Dolutegravir dosing for children with HIV weighing less than 20 kg: pharmacokinetic and safety substudies nested in the open-label, multicentre, randomised, non-inferiority … H Waalewijn, MK Chan, PDJ Bollen, HA Mujuru, S Makumbi, ... The Lancet HIV 9 (5), e341-e352, 2022 | 22 | 2022 |
| Adequate dolutegravir exposure dosed BID with rifampicin in children 6 to< 18 years H Waalewijn, HA Mujuru, P Amuge, M Cotton, P Bollen, M Chan, S Ali, ... Conference on Retroviruses and Opportunistic Infections 8 (11), 2020 | 19 | 2020 |
| Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial P Amuge, A Lugemwa, B Wynne, HA Mujuru, A Violari, CM Kityo, ... The Lancet HIV 9 (9), e638-e648, 2022 | 16 | 2022 |
| Dolutegravir twice-daily dosing in children with HIV-associated tuberculosis: a pharmacokinetic and safety study within the open-label, multicentre, randomised, non-inferiority … A Turkova, H Waalewijn, MK Chan, PDJ Bollen, ... The Lancet HIV 9 (9), e627-e637, 2022 | 15 | 2022 |
| Pharmacokinetics of dolutegravir 5mg dispersible tablets in children weighing 6 to< 20kg dosed using WHO weight bands H Waalewijn, PDJ Bollen, C Moore, A Kekitiinwa, P Amuge, H Mujuru, ... Mexico City: 10th IAS Conference on HIV Science, 21-24, 2019 | 8 | 2019 |
| Weight gain in children and adolescents on dolutegravir vs standard of care in the ODYSSEY trial A Turkova, C Kityo, HA Mujuru, E Variava, A Kekitiinwa, A Lugemwa, ... 11th IAS Conference on HIV Science 18, 21, 2021 | 5 | 2021 |
| Steady-state pharmacokinetics and early safety data in HIV-infected African children weighing≥ 25kg after switching to 50mg film-coated dolutegravir tablets in the ODYSSEY trial A Turkova, P Bollen, E Kaudha, E Chidziva, A Lugemwa, A Kekitiinwa, ... 10th International Workshop on HIV Pediatrics, 5, 2018 | 4 | 2018 |
| Pharmacokinetic Data of Dolutegravir in Second-line Treatment of Children With Human Immunodeficiency Virus: Results From the CHAPAS4 Trial LAH Bevers, H Waalewijn, AJ Szubert, C Chabala, ... Clinical Infectious Diseases 77 (9), 1312-1317, 2023 | 1 | 2023 |
| Voluntariness of consent in paediatric HIV clinical trials: a mixed-methods, cross-sectional study of participants in the CHAPAS-4 and ODYSSEY trials in Uganda S Makumbi, F Bajunirwe, D Ford, A Turkova, A South, A Lugemwa, ... BMJ open 14 (3), e077546, 2024 | | 2024 |
| OA-225 Optimising second line anchor drug options for children with HIV in Africa: 96 week results of the CHAPAS-4 randomised trial A Lugemwa, AJ Szubert, W Ndebele, S Walker, A Turkova, S Tafeni, ... BMJ Global Health 8 (Suppl 10), 2023 | | 2023 |
| Neuropsychiatric manifestations and sleep disturbances with dolutegravir-based antiretroviral therapy versus standard of care in children and adolescents: a secondary analysis … A Turkova, E White, AR Kekitiinwa, V Mumbiro, E Kaudha, A Liberty, ... The Lancet Child & Adolescent Health 7 (10), 718-727, 2023 | | 2023 |
| First pharmacokinetic data of tenofovir alafenamide fumarate and tenofovir with dolutegravir or boosted protease inhibitors in African children: a substudy of the CHAPAS-4 trial H Waalewijn, AJ Szubert, RE Wasmann, L Wiesner, C Chabala, ... Clinical Infectious Diseases 77 (6), 875-882, 2023 | | 2023 |
| Simplified dolutegravir dosing for HIV-infected children weighing≥ 20kg; multicentre pharmacokinetic and safety substudies within the ODYSSEY randomised trial P Bollen, C Moore, H Mujuru, S Makumbi, A Kekitiinwa, E Kaudha, ... The Lancet HIV, 2020 | | 2020 |
| NP-003 Steady-state pharmacokinetics and early safety data in HIV-infected african children weighing≥ 25 kg after switching to 50 mg film-coated dolutegravir tablets in the … PDJ Bollen, A Turkova, E Kaudha, E Chidziva, A Lugemwa, A Kekitiinwa, ... European Journal of Hospital Pharmacy 27 (Suppl 1), A216-A216, 2020 | | 2020 |
| simplified dolutegravir dosing for children living with HIV weighing≥ 20 kg; multicentre pharmacokinetic and safety substudies within the oDyssey randomised trial PDJ Bollen, CL Moore, E Chidziva, A Lugemwa, A Kekitiinwa, E Kaudha, ... Pushing boundaries in global dolutegravir utilization, 119, 2019 | | 2019 |
